Ann: Appendix 4C and Business Update, page-20

Don't get me wrong I think OSP has a fantastic product & as I have posted previously, the addressable market will increase with LT covid related kidney & heart damage.

https://hotcopper.com.au/posts/45961267/single - here if you are interested

Also it is a perfect fit for GE health as they make the dye & if OSP becomes 'best practice' for saving life and/or further kidney damage, based on some predefined pre-op clinical assessment, it will be all about hospitals/doctors having to use it to save getting sued out of business.

A great product & a great profitable business are sometimes two different things. I have made all the classic investor mistakes of averaging down, probably due to my confusion about these two factors. Oh well, just have to wait. Maybe rather than 600% increase in receipts, OSP could go for 300% decrease in costs & 300% increase in receipts ?
.